- Home
- URGN vs KIND Comparison
URGN vs KIND Comparison
Compare URGN & KIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- KIND
- Stock Information
- Founded
- URGN 2004
- KIND 2011
- Country
- URGN United States
- KIND United States
- Employees
- URGN N/A
- KIND N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- KIND Computer Software: Programming Data Processing
- Sector
- URGN Health Care
- KIND Technology
- Exchange
- URGN Nasdaq
- KIND Nasdaq
- Market Cap
- URGN 463.2M
- KIND 544.2M
- IPO Year
- URGN 2017
- KIND N/A
- Fundamental
- Price
- URGN $4.24
- KIND $1.54
- Analyst Decision
- URGN Strong Buy
- KIND Buy
- Analyst Count
- URGN 8
- KIND 3
- Target Price
- URGN $27.92
- KIND $2.75
- AVG Volume (30 Days)
- URGN 2.4M
- KIND 2.0M
- Earning Date
- URGN 05-12-2025
- KIND 05-07-2025
- Dividend Yield
- URGN N/A
- KIND N/A
- EPS Growth
- URGN N/A
- KIND N/A
- EPS
- URGN N/A
- KIND N/A
- Revenue
- URGN $91,871,000.00
- KIND $248,306,000.00
- Revenue This Year
- URGN $35.06
- KIND $1.77
- Revenue Next Year
- URGN $112.94
- KIND $10.72
- P/E Ratio
- URGN N/A
- KIND N/A
- Revenue Growth
- URGN 8.98
- KIND 12.01
- 52 Week Low
- URGN $3.42
- KIND $1.32
- 52 Week High
- URGN $20.70
- KIND $3.00
- Technical
- Relative Strength Index (RSI)
- URGN 27.72
- KIND 54.88
- Support Level
- URGN $3.71
- KIND $1.41
- Resistance Level
- URGN $4.25
- KIND $1.64
- Average True Range (ATR)
- URGN 0.91
- KIND 0.07
- MACD
- URGN -0.45
- KIND 0.02
- Stochastic Oscillator
- URGN 9.87
- KIND 67.19
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About KIND Nextdoor Holdings Inc.
Nextdoor Holdings Inc is the platform to connect to the neighborhoods. The purpose is to cultivate a kinder world where everyone has a neighborhood. Neighbors around the world turn to Nextdoor daily to receive trusted information, give and get help, get things done, and build real-world connections with nearby neighbors, businesses, and public services. It offers a comprehensive suite of advertising solutions designed to deliver exceptional value for businesses of all size.